Summary p53 and the murine double minute 2 (MDM2) oncoprotein expression was evaluated in paraffin-embedded tissue from 61 patients with central nervous system gliomas (53 astrocytomas and eight oligodendrogliomas) and related to proliferation-associated markers [i.e. proliferating cell nuclear antigen (PCNA), Ki-67 and nuclear organizer regions (NORs)] and epidermal growth factor receptor (EGFR). We used the monoclonal antibodies PC-1 0, MIB-1, DO-1, 1 Bi 0 and EGFR 113 and the colloid silver nitrate (AgNOR) technique. MDM2 and p53
and histological appearance from indolent well-differentiated lesions to highly anaplastic, rapidly growing neoplasms. A cardinal property of almost all types of gliomas is a propensity to recur and undergo anaplastic change (Russel and Rubinstein, 1989) . A major stimulus to the study of cell proliferation in gliomas has been the widely held belief that quantification of this fundamental process will be of value in the objective categorization of these tumours. However, while cell kinetic information is an important aspect of the biology of gliomas, it has become clear that neoplastic evolution towards glioblastoma is a multistep process that involves deregulation of several genes related to both cellular proliferation and differentiation. The molecular determinants of glioma progression are still under investigation, with considerable attention directed towards the tumour-suppressor gene p53. On the basis of findings from molecular genetic analysis, Bigner and Vogelstein (1990) have proposed the following model for malignant progression of gliomas: losses of chromosomes 17p (carrying p53 gene), 13 or 22 occur in low-grade gliomas and loss of chromosome 10 represents a critical step in transition from grade 3 to grade 4 gliomas of the astrocytic type, while abnormalities of 9p and amplification of the epidermal growth factor receptor (EGFR) stimulate further progression. Recently, the MDM2 gene was found to be amplified and overexpressed in a proportion of glioblastomas and anaplastic astrocytomas, representing the second most frequently amplified gene after the EGFR gene in these tumour types (Reifenberger et al, 1993) .
The aim of this study was to investigate the clinical significance of p53 and MDM2 oncoprotein expression in gliomas, as related to established prognostic factors, proliferation markers -proliferating cell nuclear antigen (PCNA), Ki-67 and nucleolar organizer regions (AgNORs) -and EGFR expression.
MATERIALS AND METHODS
Sixty-one patients were operated on for CNS gliomas at Asklepeion Hospital, Voula, Athens, between 1985 and . In all cases, the diagnoses were peer reviewed by two experienced pathologists. Histopathological assessment and grading were based on the principles laid down in the new World Health Organization Classification (Kleihues et al, 1993) . Our cases fell into two groups: astrocytoma and oligodendroglioma. The distribution of patients into grade and histological type categories is shown in Table 1 . As pilocytic astrocytomas and oligodendrogliomas differ substantially from diffuse astrocytomas in terms of genetic evolution and clinical behaviour and their number in our study was small, survival analysis was restricted to the group of diffuse astrocytomas (51 cases).
There were 30 men and 21 women with a mean age of 55.4 years (range 31-79 years). The follow-up period lasted 1-50 months (mean 13.5 months). By the time this study was undertaken, 46 patients had died after a mean survival of 12.4 months (1-50 months), while five patients were alive after a mean followup of 22.6 months (range 9-38 months). All patients who died had clear clinical evidence of uncontrolled tumour at the time of death. Treatment consisted of curative surgery in nine patients, radiotherapy in five patients and a combination of surgery and radiotherapy in 33 patients. Seventeen patients relapsed after a mean period of 9.6 months (range 2-41 months). The specimens had all been taken before radiotherapy was given, fixed immediately after removal in 10% formalin and processed to paraffin blocks. Only cases for which there was tissue adequate for grading and immunohistochemistry were included in this study. Representative serial sections were cut at 3-4 rm, mounted on Vectabond-treated slides and allowed to dry at 37°C overnight.
Immunohistochemistry and histochemistry
All cases were stained immunohistochemically for PCNA, Ki-67 antigen, p53 protein and MDM2 protein, and all but one case were stained for EGFR, using the standard three-step streptavidin-biotin technique. The source, dilution and incubation time for each antibody are shown in For Ki-67 antigen and MDM2 protein, the high-temperature antigen-unmasking technique was used as described by Norton et al (1994) . For (1992) . For MDM2, the threshold of positivity was raised to 5% according to Barbareschi et al (1995) . Concerning EGFR, a case was recorded as positive if it showed clear cytoplasmic and/or membrane staining beyond background.
Staining and AgNOR enumeration were performed as previously described (Korkolopoulou et al, 1994) .
Statistical analysis
The prognostic effect of various parameters with natural categorization, i.e. sex, histological grade (II, III, IV), p53 (positive vs negative), MDM2 (positive vs negative), EGFR (positive vs negative), extent of surgery (total, subtotal, partial, biopsy), radiotherapy (yes/no) and location (frontal lobe, temporal lobe, parietal lobe, occipital lobe, two lobes affected, cerebellum) was assessed by plotting Kaplan-Meier curves and comparing groups using the log-rank test (Cox, 1972) . The continuous variables, i.e. age, PCNA LI, Ki-67 LI and AgNOR score were categorized on the basis of the mean value; Ki-67 was also considered in the form of < 5% vs . 5% according to the results of a previous study (Jaros et al, 1992 p53 and MDM2 labelling were restricted to tumour cell nuclei. Oligodendrogliomas were negative for p53, and pilocytic (grade I) astrocytomas were negative for both p53 and MDM2. A fine granular staining was characteristic of lB10 antibody whereas DO-1 staining was usually stronger and had either granular or diffuse quality (Figures 4 and 5 to 75% for MDM2 (Table 3 ). The rate of positivity was significantly associated with the malignancy grade in that more positive cases for p53 and MDM2 were seen in higher grades (chi-square test, P < 0.01 for p53 and P < 0.05 for MDM2). p53 LI did not correlate with grade (P > 0.05) but MDM2 LI did (P = 0.01). Astrocytomas expressed MDM2 more often than oligodendrogliomas but the difference was not statistically significant (P > 0.05). EGFR staining was seen in 23 cases (38%). Labelling was restricted mainly to cytoplasm and in some cases also to cell membrane ( Figure 6 ). Normal nervous tissue and endothelial cells did not stain with the anti-EGFR antibody. In some tumours, the distribution of staining was uniform but in others a patchy distribution of positive cells was seen. As with p53 and MDM2, none of the grade I tumours were labelled for EGFR, and the proportion of positive tumours increased with tumour grade (chi-square test, P < 0.1). Astrocytomas were also more often positive for EGFR than oligodendrogliomas (42% vs 13%; chi-square test, P > 0.05). EGFR LI did not correlate with grade (P > 0.05).
Relationships among PCNA, Ki-67, AgNORs, p53, MDM2 and EGFR The correlation coefficients among PCNA LI, Ki-67 LI, AgNOR score, p53 LI, MDM2 LI and EGFR LI are shown in Table 4 . The relationships among the various markers are best described by the following simple linear regression equations: PCNA LI = (0.867 x Ki-67 LI) + (7.8p3 x AgNOR score); p53 LI = 0.018 x PCNA LI; Ki-67 LI = 0.341 x PCNA LI; AgNOR score = 2.408 + 0.014 x PCNA LI; MDM2 LI = 4.265 x AgNOR score; and EGFR LI = 0.250 x PCNA LI.
Survival analysis
In univariate analysis of astrocytomas, the parameters showing a significant correlation with overall survival were PCNA LI (P = 0.0025), AgNOR score (P = 0.015), tumour grade (P = 0.0137) and the age of the patient at diagnosis (P = 0.0159). p53 LI and MDM2 LI were of borderline significance (P = 0.06 and P = 0.10 respectively), whereas EGFR positivity was not significant (P = 0.64). The Kaplan-Meier curves for PCNA LI, Ki-67 LI, AgNOR score, p53 LI, MDM2 LI and EGFR LI are depicted in Figure 7 . Accordingly, the parameters influencing disease-free survival were p53 LI (P = 0.0035), AgNOR score (P = 0.0046), tumour location (P = 0.03), Ki-67 LI (P = 0.043) and grade (P = 0.046). Histological grade and Ki-67 LI were the only parameters of borderline significance influencing post-relapse survival (P = 0.07 and P = 0.09 respectively). We also examined survival in grade IV astrocytomas in relation to the combined p53/MDM2 expression. Patients with tumours displaying the p53-positive/MDM2-positive phenotype had the poorest prognosis (P = 0.06).
In multivariate analysis, the forward and backward selection strategy disclosed that factors predicting overall survival independently were PCNA LI, p53 LI, radiotherapy and age. Low PCNA LI and p53 LI, radiotherapy and young age were favourable prognostic indicators (Table 5 ). Multivariate analysis for the group of patients who relapsed showed that p53 LI, Ki-67 LI, MDM2 LI, EGFR LI, grade and the type of therapy were the statistically significant independent prognostic parameters ( Table 5) . It is noteworthy that MDM2 expression is associated with longer diseasefree survival. When survival from the first relapse was considered, statistical analysis resulted in one parameter, namely histological grade (Table 5 ).
DISCUSSION
The p53 gene, located on chromosome 17p, encodes a 53-kDa nuclear phosphoprotein which can bind to DNA and act as a transcription factor. Normal p53 is believed to function as an inhibitor of cell replication when DNA damage is sustained. It is generally undetectable by standard immunohistochemistry because of its low cellular levels and a very short half-life (Finlay, 1989) . Mutations of the gene occurring within the coding region usually lead to the production of a non-functional protein which, being much more stable than the wild protein, accumulates in the nucleus reaching (Iggo et al, 1990) . On the other hand, in addition to being of wild type, p53 may not be detectable immunohistochemically because the gene is deleted or a stop codon has formed (Maestro et al, 1992) . Moreover, p53 protein can be stabilized and therefore detected immunohistochemically by binding to various proteins, such as large T antigen, 70-kDa heat-shock protein (Lane, 1992) and MDM2 protein. The last is a 90-kDa protein that has the ability to form complexes with both wild and mutant types of p53 and acts as a specific p53 antagonist by concealing its activation domain (Momand et al, 1992 ). An autoregulatory feedback loop seems to exist between MDM2 and p53 in the sense that the MDM2 gene is inducible by wild p53 protein whereas MDM2 protein regulates p53 protein at the level of its activity. This loop maintains a critical MDM2-p53 ratio within the cell (Meltzer, 1994) . In vivo, the MDM2 gene is commonly amplified in soft tissue sarcomas (Cordon-Cardo et al, 1994) . The functional link between p53 and MDM2, however, may not be as clear as is believed, at least in some cellular systems, and MDM2 may have other functions unrelated to those resulting from interactions with p53 (Xiao et al, 1995) . Molecular studies of human gliomas have demonstrated that approximately 25-45% of them harbour p53 gene mutations (mainly missense mutations) (Louis, 1994) . There is a plethora of recent papers on p53 immunohistochemical demonstration in gliomas (Barbareschi et al, 1992; Haapasalo et al, 1993; Newcomb et al, 1993; Soini et al, 1994; Kyritsis et al, 1996) in which positive staining was found in 40-65% of cases, a figure similar to that quoted in the present study. The discrepancy between p53 mutations and p53 immunopositivity has been attributed mainly to wild p53 protein accumulation , although mutations outside the conserved region cannot be excluded (Kyritsis et al, 1996) . Cytoplasmic staining as reported by other authors (Barbareschi et al, 1992; Soini et al, 1994) was not observed in our series. p53 positivity was restricted to astrocytic cell lineage, in keeping with the very low frequency of p53 mutations in non-astrocytic gliomas (Ohgaki et al, 1991) . p53 positivity tended to be associated with a high-grade histology in accordance with previous studies (Barbareschi et al, 1992; Soini et al, 1994) . Similarly, MDM2 protein was expressed in 48% of cases and was significantly associated with a high-grade phenotype. The much higher percentage of gliomas expressing MDM2 than gliomas with MDM2 gene amplification (8-10%) reported by Reifenberger et al (1993) probably reflects increased transcription of the gene or post-translational stabilization of MDM2 protein.
The majority of cases expressing p53 also overexpressed MDM2, implying that either MDM2 overexpression is responsible for the stabilization of wild p53 protein or there is an underlying p53 mutation possessing MDM2 transactivation abilities. The fact, however, that a substantial number of cases express MDM2 but not p53 suggests a p53-independent mechanism of MDM2 overexpression. Finally, the p53-positive/MDM2-negative phenotype is indicative of a p53 mutation that is unable to activate the MDM2 gene. The relationship between p53 and proliferation indices is in agreement with data showing that p53 mRNA levels increase in association with cell proliferation (Reich and Levine, 1984) and could be linked to the effect that p53 exerts on the PCNA gene (Mercer et al, 1991) . Interestingly, a relationship was also established between MDM2 and proliferation. A plausible explanation is that increased MDM2 expression inactivates p53, blocking its antiproliferative function. There is a limited number of studies addressing the possible association of p53 immunopositivity with poor prognosis (Jaros et al, 1992; Soini et al, 1994) , the findings of which agree with ours, although unpublished data reported by Louis et al (1994) have failed to confirm this association. Taking into account that p53 mutations are commoner in younger patients and in astrocytomas progressing stepwise to glioblastomas (van Meyel et al, 1994) , it is tempting to hypothesize that patients whose tumours carry p53 mutations may survive longer. Although this assumption is seemingly at discrepancy with our results, one must bear in mind that p53 immunopositivity in gliomas is in many cases due to wild type protein accumulation and that the stabilization of the wild p53 protein -and not the p53 gene status per se -may in itself facilitate glioma progression . In this perspective, evaluation of the combined MDM2/p53 protein phenotype could have prognostic relevance and may be more informative than evaluation of the p53 or MDM2 protein alone, as suggested by our findings in grade IV astrocytomas.
The EGFR gene is found on chromosome 7. It encodes a 170-kDa transmembrane glycoprotein with an extracellular ligandbinding domain, a transmembrane region and an intracellular portion with tyrosine kinase activity (Hunter, 1984) . Amplification and rearrangement of the EGFR gene with overexpression of its product have been reported in 40-50% of glioblastoma multiforme and in a minority of anaplastic astrocytomas (Liberman et al, 1984; Reifenberger et al, 1989 Reifenberger et al, , 1993 Diedrich et al, 1995) . Our results concur with these findings. The association between p53 LI and EGFR LI, as well as the simultaneous expression of these two molecules in a significant proportion (23%) of our cases, suggests that p53 and EGFR may be involved in early stages of glial tumorigenesis, as hypothesized by Jaros et al (1992) and Rasheed et al (1994) , and that this expression may be associated with progression to more anaplastic forms of gliomas. The cytoplasmic distribution of EGFR that we and others (Jaros et al, 1992) have observed may be explained by rapid internalization of the EGF-EGFR complex or by cytoplasmic binding of EGFR to TGFa (Jaros et al, 1992) . In univariate analysis, EGFR expression failed to emerge as a significant predictor of survival, in contrast to the findings of Diedrich et al (1995) and Zhu et al (1996) . The latter, however, studied only irradiated tumours.
Various studies performed in this and other laboratories have shown an overall positive correlation between histological grade of gliomas and cellular proliferation parameters, including Ki-67 (or MIB-1) LI (Burger et al, 1986; Zuber et al, 1988; Schroder, 1991; Karamitopoulou et al, 1994; Sallinen et al, 1994) , PCNA LI (Allegranza et al, 1991; Louis et al, 1991; Karamitopoulou et al, 1993; Korkolopoulou et al, 1993) and AgNOR number (Maier et al, 1990; Plate et al, 1991; Korkolopoulou et al 1993) , lending support to the findings of the present study. However, there is significant overlap in the expression of proliferation indices among various grades, so that none of them can be used as a reliable grading tool. In a previous study (Korkolopoulou et al, 1994) , we found that PCNA LI has a significant impact on glioma survival. The present study strengthens this finding, as well as the prognostic significance of the other indices of cell proliferation (i.e. Ki-67 LI and AgNOR score) (Kajiwara et al, 1990; Sallinen et al, 1994) . However, other authors have failed to substantiate the prognostic effect of proliferation indices in gliomas (Zuber et al, 1988; Nicoll et al, 1991; Figge et al, 1992; Karkavelas et al, 1995) . The rather strong relationship between the three proliferationassociated indices we have used is also in agreement with previously reported findings (Korkolopoulou et al, 1993; Sallinen et al, 1994) .
To our knowledge, our study is the first to correlate proliferation data, p53 and MDM2 oncoprotein expression and EGFR expression with survival in gliomas. Multivariate analysis demonstrated that overall survival in astrocytomas can be predicted by the age of the patient, PCNA LI, p53 LI and radiotherapy. The information conveyed by these parameters is superior to that yielded by conventional histopathological grading. This is in agreement with the findings of previous studies (Korkolopoulou et al, 1994; Vigliani et al, 1994) . The failure of other authors to establish an independent prognostic significance for PCNA LI may be because of different staining protocols and scoring methods (Theunissen and Blaauw, 1993; Sallinen et al, 1994) . On the contrary, p53 LI and MDM2 LI were the most statistically significant parameters in predicting disease-free survival independently. However, MDM2 LI did not attain a statistical significance in univariate analysis because its direct favourable prognostic effect was masked by its relationship with histological grade, p53 LI and proliferation indices. Finally, histological grade was superior to the aforementioned parameters only in predicting post-recurrence survival.
In conclusion, this study establishes the prognostic value of cell proliferation indices , oncoprotein expression (p53 and MDM2) and EGFR in overall and disease-free survival of patients with diffuse astrocytomas. More importantly, it demonstrates that PCNA LI and p53 LI are more significant predictors of overall survival than histological grade. The only other factors with independent prognostic significance are the age of the patient and the type of treatment. Should these observations be validated by prospective studies, the above parameters could be incorporated into the routine evaluation of astrocytomas to improve the prognostic accuracy of the current histopathological criteria.
